NewsBenzingaTempus AI celebra un acuerdo plurianual con Bristol Myers Squibb para que BMY licencie datos oncológicos multimodales hasta 2031, con el fin de apoyar la identificación de información biológica y clínica, el descubrimiento de nuevos objetivos... Tempus AI celebra un acuerdo plurianual con Bristol Myers Squibb para que BMY licencie datos oncológicos multimodales hasta 2031, con el fin de apoyar la identificación de información biológica y clínica, el descubrimiento de nuevos objetivos... Benzinga 2026.10.23 13:11 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients